- What is iCardio.ai's primary focus?
- iCardio.ai develops AI for the interpretation of ultrasound imaging, specifically focusing on echocardiograms to detect and treat heart disease.
- What is iCardio.ai's mission?
- iCardio.ai's mission is to revolutionize the way heart disease is detected and treated by providing accessible, accurate, and automated interpretation of cardiac imaging, thereby democratizing quality cardiovascular health globally.
- What FDA clearances has iCardio.ai received?
- iCardio.ai has received FDA 510(k) clearance for its artificial intelligence software for echocardiography interpretation, including EchoMeasure™ for automated echo measurements and CardioVision™ for auto-detecting aortic stenosis.
- When was iCardio.ai founded?
- iCardio.ai was founded in 2019.
- Where is iCardio.ai headquartered?
- iCardio.ai is headquartered in Los Angeles, United States.
- Who are the co-founders of iCardio.ai?
- The co-founders of iCardio.ai include Joseph Sokol (CEO), Dr. Aakriti Gupta (Chief Medical Advisor), Dr. Roman Sandler (Chief Technology Officer), and Dr. Joshua Penn.
- What technologies does iCardio.ai utilize?
- iCardio.ai utilizes machine learning, deep learning, and AI technologies in its solutions.
- What are iCardio.ai's target customer segments?
- iCardio.ai targets clinicians, enterprises, and ultrasound companies as its customers.
